This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Baxter Highlights Commitment To Innovation And Focus On Improving Patient Outcomes At WFH World Congress

Baxter International Inc. (NYSE: BAX) showcased its commitment to innovation in hemophilia today with the presentation of new data from 60 oral and poster presentations during the 2014 World Federation of Hemophilia (WFH) World Congress in Melbourne, Australia (May 11-15). The data include safety, efficacy and immunogenicity findings on Baxter’s global leading brands and new treatments for hemophilia A, von Willebrand disease and other coagulation disorders.

''Baxter’s investigational pipeline spans multiple programs, underscoring Baxter’s scientific commitment to advancing care for patients with rare and chronic conditions,'' said Ludwig Hantson, Ph.D., president of Baxter BioScience. ''Baxter remains committed to the research and development of new treatments and product enhancements that improve the safety, efficacy and cost-effectiveness of treatments, as well as broadening access to quality care for hemophilia patients worldwide.''


Data presented during WFH include several studies of Baxter’s late-stage R&D pipeline, including BAX 855, Baxter’s extended half-life investigational recombinant factor VIII (rFVIII) treatment for hemophilia A. BAX 855 is based on the full-length ADVATE [Antihemophilic Factor (Recombinant)] molecule, and is modified with PEGylation technology to extend its duration of activity in the body. As Baxter continues to evaluate the efficacy and safety of this extended half-life treatment in clinical studies, the data from these studies demonstrate the investigational treatment’s structural and functional integrity.

Multiple studies will be presented on ADVATE, including a meta-analysis of ADVATE-PASS (Post-Authorization Safety Studies), a prospective, uncontrolled, open-label study, documenting the real-world clinical experience with ADVATE. Conducted in multiple countries between July 2003 and January 2014, the results presented at WFH are the first to illustrate the safety and efficacy of routine use of a rFVIII concentrate in patients with hemophilia A and a low titer inhibitor or inhibitor history. Earlier analysis of PASS data also showed a favorable overall safety and efficacy profile for ADVATE. 1

Several presentations also support OBI-1, Baxter’s investigational recombinant porcine sequence factor VIII treatment. The investigational treatment has completed a phase II/III study and is now under regulatory review in the United States for the treatment of acquired hemophilia A, a rare, potentially life-threatening bleeding disorder that typically affects older adults and occurs equally in males and females. These data offer insights into the safety, efficacy, and immunogenicity of OBI-1 in patients with acquired hemophilia A.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GOOG $693.00 0.29%
TSLA $240.75 -2.80%
YHOO $36.61 0.06%
AAPL $93.75 -1.10%
FB $117.53 0.69%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs